MX2024006042A - Metodos para tratar dolores de cabeza y migra?as con inhibidores de la subunidad alfa 11 del canal dependiente de voltaje de sodio (scn11a). - Google Patents
Metodos para tratar dolores de cabeza y migra?as con inhibidores de la subunidad alfa 11 del canal dependiente de voltaje de sodio (scn11a).Info
- Publication number
- MX2024006042A MX2024006042A MX2024006042A MX2024006042A MX2024006042A MX 2024006042 A MX2024006042 A MX 2024006042A MX 2024006042 A MX2024006042 A MX 2024006042A MX 2024006042 A MX2024006042 A MX 2024006042A MX 2024006042 A MX2024006042 A MX 2024006042A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- scn11a
- alpha subunit
- migraines
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163281640P | 2021-11-20 | 2021-11-20 | |
| PCT/US2022/080208 WO2023092112A1 (en) | 2021-11-20 | 2022-11-21 | Methods of treating headaches and migraines with sodium voltage-gated channel alpha subunit 11 (scn11a) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006042A true MX2024006042A (es) | 2024-06-04 |
Family
ID=84829809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006042A MX2024006042A (es) | 2021-11-20 | 2022-11-21 | Metodos para tratar dolores de cabeza y migra?as con inhibidores de la subunidad alfa 11 del canal dependiente de voltaje de sodio (scn11a). |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230279400A1 (https=) |
| EP (1) | EP4433090A1 (https=) |
| JP (1) | JP2024541089A (https=) |
| KR (1) | KR20240109247A (https=) |
| CN (1) | CN118234513A (https=) |
| AU (1) | AU2022393586A1 (https=) |
| CA (1) | CA3237033A1 (https=) |
| IL (1) | IL312312A (https=) |
| MX (1) | MX2024006042A (https=) |
| WO (1) | WO2023092112A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025037925A1 (ko) | 2023-08-16 | 2025-02-20 | 주식회사 엘지에너지솔루션 | 이차전지용 양극 및 이를 포함하는 이차전지 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US96183A (en) * | 1869-10-26 | Improved ciiothes-mne supporter | ||
| EP2769724A1 (en) * | 2013-02-22 | 2014-08-27 | Université d'Aix-Marseille | Inhibitors of Na(v) 1.9 channel activity and uses thereof for treating pain |
| US9139648B1 (en) * | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| JP6782412B2 (ja) * | 2014-11-25 | 2020-11-11 | 国立大学法人京都大学 | 疼痛遺伝子及びその用途 |
| CN108530534B (zh) * | 2017-03-03 | 2021-06-18 | 易森荟(武汉)生物医药有限公司 | Nav1.9的靶点多肽、与其结合的抗体及抗体片段和相关药物组合物 |
-
2022
- 2022-11-21 US US18/057,298 patent/US20230279400A1/en active Pending
- 2022-11-21 KR KR1020247015157A patent/KR20240109247A/ko active Pending
- 2022-11-21 WO PCT/US2022/080208 patent/WO2023092112A1/en not_active Ceased
- 2022-11-21 JP JP2024529509A patent/JP2024541089A/ja active Pending
- 2022-11-21 AU AU2022393586A patent/AU2022393586A1/en active Pending
- 2022-11-21 CN CN202280074256.XA patent/CN118234513A/zh active Pending
- 2022-11-21 IL IL312312A patent/IL312312A/en unknown
- 2022-11-21 CA CA3237033A patent/CA3237033A1/en active Pending
- 2022-11-21 EP EP22839091.0A patent/EP4433090A1/en active Pending
- 2022-11-21 MX MX2024006042A patent/MX2024006042A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN118234513A (zh) | 2024-06-21 |
| IL312312A (en) | 2024-06-01 |
| WO2023092112A1 (en) | 2023-05-25 |
| US20230279400A1 (en) | 2023-09-07 |
| CA3237033A1 (en) | 2023-05-25 |
| AU2022393586A1 (en) | 2024-05-09 |
| KR20240109247A (ko) | 2024-07-10 |
| EP4433090A1 (en) | 2024-09-25 |
| JP2024541089A (ja) | 2024-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023002956A1 (es) | Inhibidor de la proteasa 1 específica de ubiquitina (usp1) | |
| MX2023008420A (es) | Combinación de un inhibidor de dominios asociados mejorados transcripcionales (tead) de 3-(imidazol-4-il)-4-(amino)- bencenosulfonamida con un inhibidor del factor de crecimiento epidérmico (egfr) y/o un inhibidor de proteína cinasa-cinasas activadas por mitógen (mek) para usarse en el tratamiento de cáncer de pulmón. | |
| MX2020002032A (es) | Inhibidores de bcl-2. | |
| MX2023013912A (es) | Metodos para inhibir ras. | |
| NO20054640L (no) | Fremgangsmater for behandling av Parkinsons sykdom | |
| MX2021003187A (es) | Inhibición de la peptidasa específica de ubiquitina 9x. | |
| CR20240296A (es) | Inhibidores parp1 | |
| GEAP202215479A (en) | Magl inhibitors | |
| MX2021013148A (es) | Dispositivo de enfriamiento y metodo para fabricar el dispositivo de enfriamiento. | |
| MX2024008461A (es) | Metodos para tratar trastornos linfoproliferativos malignos. | |
| MX2024006042A (es) | Metodos para tratar dolores de cabeza y migra?as con inhibidores de la subunidad alfa 11 del canal dependiente de voltaje de sodio (scn11a). | |
| PH12021551750A1 (en) | Treatment of hepatotoxicity | |
| WO2021162981A3 (en) | Methods and compositions for identifying castration resistant neuroendocrine prostate cancer | |
| MX2024003475A (es) | Polimorfos como inhibidores de erbb. | |
| CO2022000266A2 (es) | Inhibidores de enzimas | |
| WO2021195470A3 (en) | Identification and use of compounds in the treatment or prevention of severe acute respiratory syndrome coronavirus 2 | |
| MY207202A (en) | Signal processing method and device | |
| EP4364811A3 (en) | Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin | |
| MX2025004193A (es) | Inhibidores del inhibidor 1 de activador de plasminogeno (pai-1) y usos de los mismos | |
| WO2019204332A3 (en) | Pak4 inhibitors and methods of use | |
| MX2022008532A (es) | Inhibidores de hidrocarburo de arilo (ahr) y usos de estos. | |
| ZA202103914B (en) | Cxcr7 inhibitors for the treatment of cancer | |
| MX2022011844A (es) | Terapia combinada con un inhibidor de idh mutante. | |
| MX2024004171A (es) | Tratamientos conjuntos que usan inhibidores de la proteina arginina n-metil transferasa 5 (prmt5) para el tratamiento de cancer. | |
| MX2021006540A (es) | Compuestos farmaceuticos y su uso como inhibidores de proteasa 19 especifica de ubiquitina (usp19). |